Лучшие больницы для «Bone Cancer Treatment» в Дубай, ОАЭ

Bone cancer treatment costs vary significantly based on tumor type, stage, the surgical procedure required, and the number of chemotherapy or radiation cycles needed. In India, at JCI- and NABH-accredited sarcoma centers, the total treatment cost — including limb-salvage surgery with megaprosthesis, neoadjuvant and adjuvant chemotherapy, hospitalization, and post-operative rehabilitation — typically ranges from USD 6,000 to USD 35,000. A biopsy-only workup or a single chemotherapy phase would fall at the lower end; complex en-bloc pelvic resection with reconstruction and a full 6-month chemotherapy protocol would approach the upper end. In the UAE, at JCI- and DHA-accredited hospitals in Dubai or Abu Dhabi, equivalent treatment costs between USD 15,000 and USD 80,000, reflecting higher facility fees, imported implant costs, and the premium private hospital infrastructure. India is generally 50–65% more cost-effective than the UAE for the same clinical standard. GAF Healthcare provides a personalized, itemized cost estimate for your specific case based on review of your medical records before you commit to travel.

The minimum safe stay before long-haul international air travel following bone cancer treatment is 6 to 10 weeks, and in most cases involving major limb-salvage surgery combined with chemotherapy, 8–10 weeks is the realistic expectation. Fit-to-fly clearance requires that several criteria are simultaneously met: the surgical wound must be fully healed without evidence of infection or dehiscence; the post-operative DVT risk window (highest in the first 4–6 weeks after major orthopedic surgery) must be manageable with prophylactic low-molecular-weight heparin during the flight; the patient must be independently mobile with gait aids and able to tolerate prolonged seated positioning; post-operative chemotherapy cycles must have commenced so that the adjuvant protocol can be handed over to the home oncologist; and pain must be controlled on oral medications without requirement for intravenous analgesia. Patients receiving neoadjuvant chemotherapy prior to surgery may need to begin their in-country stay up to 10–14 weeks before surgery, significantly extending total time abroad if they wish to complete the full protocol in India or the UAE. GAF Healthcare's treating team issues a formal fit-to-fly letter prior to discharge, and compression stockings plus in-flight LMWH are prescribed for all patients with major bone surgery undergoing flights exceeding 4 hours.

Success rates for bone cancer treatment depend critically on tumor histology, anatomical site, stage at diagnosis, and response to chemotherapy. For localized osteosarcoma (the most common primary bone malignancy) treated with the MAP chemotherapy protocol and limb-salvage surgery, the 5-year overall survival rate is 60–80% at high-volume sarcoma centers. Patients whose resected tumors show ≥90% necrosis on histological assessment (Huvos Grade III–IV, indicating a good chemotherapy response) have 5-year survival rates approaching 75–85%, compared to 45–55% for poor responders. For localized Ewing sarcoma treated with VDC/IE chemotherapy and local control (surgery and/or radiation), 5-year survival rates range from 65–75%. Low-grade chondrosarcoma treated with wide surgical excision has an excellent prognosis with cure rates exceeding 85–90%, as chondrosarcoma is largely resistant to chemotherapy and radiation, making surgical margin quality the dominant prognostic factor. For metastatic disease at diagnosis (present in approximately 15–20% of osteosarcoma patients), 5-year survival is approximately 20–30% despite aggressive multimodal therapy. Giant cell tumor of bone (malignant variant) has a 5-year survival exceeding 70% with appropriate surgery and denosumab. GAF Healthcare partners exclusively with high-volume sarcoma centers — institutions performing over 100 sarcoma surgeries annually — where institutional outcomes align with or exceed these benchmarks.